Lv4
640 积分 2022-11-01 加入
G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D) AND B-CELL MATURATION ANTIGEN (BCMA) BI-SPECIFIC DUAL CAR EFFECTIVELY ADDRESS ANTIGEN ESCAPE AND TUMOR HETEROGENEITY CHALLENGE IN MULTIPLE MYELOMA (MM)
4天前
已完结
246 A GPRC5D and BCMA bispecific CAR-T product demonstrated dual antigen targeting capability and efficacy against multiple myeloma cells bearing BCMA mutations associated with treatment resistance
4天前
已完结
Antigen‐binding site anatomy and somatic mutations in antibodies that recognize different types of antigens
5天前
已完结
Democratizing deliberative systems
1个月前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
1个月前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
2个月前
已完结
Exploring the NK cell platform for cancer immunotherapy
3个月前
已完结
ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion
3个月前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
3个月前
已完结
IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies
3个月前
已完结
皖公网安备34019202002308
